Which medications in the drug class Alpha 4 Integrin Inhibitors are used in the treatment of Inflammatory Bowel Disease?

Updated: Apr 10, 2020
  • Author: William A Rowe, MD; Chief Editor: BS Anand, MD  more...
  • Print

Alpha 4 Integrin Inhibitors

Integrin inhibitors are emerging as options for moderate-to-severe IBD in patients who have had an inadequate response with, lost response to, or were intolerant to a TNF blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.

Natalizumab (Tysabri)

Natalizumab is a recombinant humanized IgG4-1C monoclonal antibody produced in murine myeloma cells. It binds to alpha-4 subunits of α4β1 and α4β7 integrins expressed on the leukocyte surface, which inhibit α4-mediated leukocyte adhesion to their receptors. In Crohn disease, the interaction of the α4β7 integrin with the endothelial receptor MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of the disease.

Vedolizumab (Entyvio)

Vedolizumab is a recombinant humanized monoclonal antibody that binds specifically to α4β7 integrin. It blocks the interaction of α4β7 integrin with a gut-associated addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. It is indicated for both ulcerative colitis and Crohn disease.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!